Genus (GNS)

Sector:

Pharma and Biotech

Index:

FTSE 250

3,710.00p
   
  • Change Today:
    -62.00p
  • 52 Week High: 6,070.00
  • 52 Week Low: 3,610.00
  • Currency: UK Pounds
  • Shares Issued: 65.77m
  • Volume: 127,185
  • Market Cap: 2,440.07m
  • RiskGrade: 128
Select chart: 1 week | 1 month | 3 month | 6 month | 1 year
 

Current

1 week

Forecasts

Year Ending Revenue (m) Pre-tax (m) EPS P/E PEG EPS Grth. Div Yield
30-Jun-22 603.29 78.87 93.92p 40.2 n/a -7% 33.61p 0.9%
30-Jun-23 654.60 91.71 109.45p 34.5 2.1 +16% 36.70p 1.0%

Copyright © 2022 FactSet Research Systems Inc. All rights reserved.

Trends & Recommendations

  Current 1 week ago 1 month ago 3 months ago 6 months ago 1 year ago
Revenue (m)
30-Jun-2022 603 603 604 610 614 639
30-Jun-2023 655 655 n/a n/a n/a n/a
 
Earnings
30-Jun-2022 93.92p 93.92p 94.18p 100.17p 106.81p 108.76p
30-Jun-2023 109.45p 109.45p n/a n/a n/a n/a
 
Dividend
30-Jun-2022 33.61p 33.61p 33.71p 34.05p 34.26p 34.03p
30-Jun-2023 36.70p 36.70p n/a n/a n/a n/a
 
Recommendations
Strong Buy 4 4 4 2 4 5
Buy 0 0 0 1 1 0
Neutral 2 2 2 3 1 2
Sell 0 0 0 0 0 0
Strong Sell 0 0 0 0 0 0
No. of Brokers 6 6 6 6 6 7
 
Average Rec 8.33 8.33 8.33 7.08 8.75 8.57

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Broker estimates sourced from FactSet Estimates +44 (0) 20 3009 7000. FactSet Estimates calculate consensus using only those estimates changed or actively validated within the last 75 days.

Note 4: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 5: Forecast figures based on normalised accounts.

 

IFRS Changes - Find Out More

Find out about IFRS and how this affects the financial infomation for all UK companies.

Genus Market Data

Currency UK Pounds
Share Price 3,710.00p
Change Today -62.00p
% Change -1.64 %
52 Week High 6,070.00
52 Week Low 3,610.00
Volume 127,185
Shares Issued 65.77m
Market Cap 2,440.07m
RiskGrade 128

Genus Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
96.26% below the market average96.26% below the market average96.26% below the market average96.26% below the market average96.26% below the market average
91.84% below the sector average91.84% below the sector average91.84% below the sector average91.84% below the sector average91.84% below the sector average
Price Trend
49.29% below the market average49.29% below the market average49.29% below the market average49.29% below the market average49.29% below the market average
30.16% below the sector average30.16% below the sector average30.16% below the sector average30.16% below the sector average30.16% below the sector average
Income
87.97% below the market average87.97% below the market average87.97% below the market average87.97% below the market average87.97% below the market average
80% below the sector average80% below the sector average80% below the sector average80% below the sector average80% below the sector average
Growth
80.26% above the market average80.26% above the market average80.26% above the market average80.26% above the market average80.26% above the market average
60.00% above the sector average60.00% above the sector average60.00% above the sector average60.00% above the sector average60.00% above the sector average

What The Brokers Say

Strong Buy 4
Buy 0
Neutral 2
Sell 0
Strong Sell 0
Total 6
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Genus Dividends

  Latest Previous
  Final Interim
Ex-Div 18-Nov-21 04-Mar-21
Paid 10-Dec-21 01-Apr-21
Amount 21.70p 10.30p

Trades for 28-Jan-2022

Time Volume / Share Price
16:35 57 @ 3,710.00p
16:35 85,070 @ 3,710.00p
16:29 28 @ 3,716.00p
16:29 74 @ 3,710.00p
16:29 66 @ 3,710.00p

Genus Key Personnel

CEO Stephen Wilson
CFO Alison Henriksen

Top of Page